BIO 2022: Addressing Bottlenecks in Gene Therapy
While there have been enormous advancements in gene therapies, these progress also bring new challenges, from manufacturing complications to safe delivery systems. As a new era of gene therapy ushers in, how are the next generation of genetic therapeutics going to address these issues? In a panel titled A New Era in Gene Therapy on June 15 at the 2022 BIO International Convention, industry experts discussed novel developments that could solve some of the greatest headaches in gene therapy, such as the application of non-viral vectors, improving access to gene therapy for rare and broad indication, and enhancing cost efficiency.
A New Era in Gene Therapy’s panelists included:
- Shankar Ramaswamy, CEO and Founder of Kriya Therapeutics
- Diem Nguyen, CEO of Xalud Therapeutics
- Mathew Pletcher, Division Head of Gene Therapy Research & Technical Operations for Astellas Gene Therapies
- RA Session II, CEO and Founder of Taysha Gene Therapies
It's free! Log in now to read
LATEST
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115